Alcon Cilodex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alcon Cilodex

Quick Facts

Property Description
Active Ingredients Ciprofloxacin, Dexamethasone
Form Sterile Suspension (Otic or Ophthalmic Solution)
Pharmacological Class Antibiotic and Corticosteroid Combination
Common Use Management of bacterial infection and inflammation
Origin Synthetic

What Type of Medicine is the Ciprofloxacin and Dexamethasone Combination?

The medicine is a prescription-only, dual-action combination product whose two main components belong to the pharmacological classes of Antibiotics (Ciprofloxacin, a fluoroquinolone) and Corticosteroids (Dexamethasone, a glucocorticoid). Both active components are entirely synthetic in origin and are designed for topical administration. This fixed combination provides a single agent intended for managing the dual pathology—infection and inflammation—often seen in conditions such as outer ear infections.

Composition and Unique Topical Dosage Form

This product is a sterile preparation supplied as a suspension—specifically, an otic solution for the ear or an ophthalmic solution for the eye. The formulation contains Ciprofloxacin as the anti-infective and Dexamethasone as the anti-inflammatory agent. The dosage form, a preserved, sterile suspension, allows the two active agents to be delivered simultaneously in high concentration directly to the affected, localized area, minimizing systemic exposure. This specialized application route highlights the product's focus on targeted, local treatment.

General Therapeutic Purpose of the Combined Action

The general therapeutic purpose of the product is to provide comprehensive local management in conditions characterized by both an active bacterial pathogen and significant inflammation. The dual-action formulation utilizes the bactericidal effect of Ciprofloxacin to address the underlying microbial cause while Dexamethasone concurrently works to reduce inflammation, thereby mitigating pain and swelling. This combined approach is intended to achieve relief and resolution of both the infection and the patient's acute discomfort.

Regulatory References

  1. NIH DailyMed: CIPRODEX Otic Suspension

What side effects are possible with Alcon Cilodex?

Possible side effects and safety information

The regulatory safety profile for the Ciprofloxacin and Dexamethasone otic suspension is categorized by government authorities to classify potential adverse reactions and safety constraints. The reported side effects are primarily local and are grouped according to System-Organ Classes.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency based on observations from clinical trials documented in regulatory labeling. Common effects (occurring in 1% to 10% of patients) primarily include localized reactions such as ear discomfort, ear pain, and ear pruritus (itching). Less common reported reactions include taste perversion, ear precipitate, and irritability.

Safety Considerations and Limitations

System-Organ Classes most frequently affected are Ear and Labyrinth Disorders, which encompass the most common local reactions, followed by Nervous System Disorders (e.g., headache, dizziness) and Gastrointestinal Disorders (e.g., vomiting, taste perversion).

Serious Adverse Reactions documented in regulatory sources include the potential for Hypersensitivity Reactions (such as anaphylaxis) associated with the quinolone class (Ciprofloxacin). These reactions are rare but require immediate discontinuation upon the first sign of a rash or allergic response.

Population-Specific Safety: Safety and effectiveness are established only in pediatric patients 6 months of age and older. The medication is classified as Pregnancy Category C, advising caution as adequate human studies are lacking.

Safety Restrictions: The product is contraindicated if the ear infection is known to be caused by a virus (e.g., Herpes Simplex) or a fungus. The label also notes that prolonged use may lead to the overgrowth of non-susceptible organisms.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for the ciprofloxacin and dexamethasone topical suspension indicates a low risk of systemic toxicity in the event of local overexposure. Due to the characteristics of the preparation and minimal systemic absorption, official regulatory labeling states that no toxic effects are to be expected with an overdose administered through the ear.

Emergency Actions and Acute Reactions

While dose-dependent toxicity is not expected, regulatory authorities mandate specific emergency actions for acute adverse events.

When to Seek Immediate Medical Help

Immediate emergency medical attention is required for the signs of a serious acute hypersensitivity reaction to the ciprofloxacin component. Such severe, life-threatening manifestations are documented to include:

  • Cardiovascular collapse or loss of consciousness.
  • Airway obstruction, dyspnea, or laryngeal and pharyngeal edema (angioedema).
  • Severe, rapidly spreading urticaria or itching.

In the event of accidental swallowing of the ear drops, individuals should immediately contact a Poison Control center or seek emergency medical attention. For severe acute hypersensitivity, officially documented interventions include the administration of oxygen and airway management.

Antidote and Management

No specific antidote for overdose is listed in the official prescribing information. Management is supportive, focused on addressing the patient's symptoms and maintaining vital functions, particularly when responding to an acute hypersensitivity event.

Therapeutic Uses of Alcon Cilodex

What Alcon Cilodex Treats: Main Uses and Benefits

This medication is an ear drop suspension containing an antibiotic and a steroid, commonly used across domains where additional symptomatic support is needed.

This combination product is used to help address the acute conditions of outer ear infections (Swimmer's Ear) and middle ear infections in children who have had ear tubes (tympanostomy tubes) placed.

The medication is applied in addressing symptoms related to the bacterial infection and is relevant for easing the pronounced pain, swelling, and redness that accompany it. This comprehensive support helps address symptoms that become more disruptive during flare-ups.

“It is commonly used when symptoms create noticeable physiological strain and short-term symptomatic assistance is needed.”


Key Therapeutic Domains

The medication is commonly applied in clinical settings that involve acute or disruptive symptom patterns, particularly those affecting the outer ear. It is used to help address the underlying bacterial pathology and symptoms that create noticeable functional strain while simultaneously contributing to easing the resulting discomfort and physiological strain. This symptomatic relief may assist with maintaining functional stability during difficult episodes.

Quick Fact: Symptomatic Support for Ear Discomfort

The use of this medication is relevant for easing symptoms like ear discharge or drainage, and may assist with maintaining functional stability during periods of heightened distress.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Alcon Cilodex — official regulatory information

The eligibility profile for ciprofloxacin/dexamethasone otic suspension is defined by absolute contraindications and specific population limitations as stated in government labeling (FDA/EMA).

Classification Official Regulatory Statement
Populations for whom use is allowed Adults, the Elderly, and Pediatric patients six months of age and older.
Populations for whom use is contraindicated Patients with known hypersensitivity to ciprofloxacin, dexamethasone, other quinolones, or corticosteroids.
Individuals with active viral infections of the external ear canal (e.g., Herpes Simplex) or fungal (mycotic) otic infections.
Age-related eligibility rules Safety and effectiveness have not been established in pediatric patients under six months of age.
Pregnancy and lactation eligibility status Pregnancy: Use is generally not recommended unless the benefit justifies the potential risk. Lactation: Use with caution is advised; a decision is required whether to discontinue nursing or discontinue the drug.

Official eligibility statements:

  • The medication is contraindicated if the underlying ear infection is caused by a virus or a fungus.
  • Eligibility is strictly defined by an age threshold of six months and the absence of a history of hypersensitivity to the drug's components or related drug classes.

Connection to the overall eligibility profile Official regulatory documents establish non-eligibility primarily through absolute contraindications based on disease etiology (viral/fungal infections) and allergy history. Use is otherwise generally permitted for patients six months and older, with clear regulatory conditions applied to the populations of pregnancy and lactation.

What should I know about interactions with other medicines?

The official interaction profile for the Ciprofloxacin/Dexamethasone otic suspension is largely determined by its low systemic exposure after topical administration, which leads to a minimal risk of clinically relevant drug interactions. Regulatory bodies conclude that most common pharmacokinetic interactions are unlikely to occur with this topical preparation.


Pharmacokinetic Interaction Potential

Due to minimal absorption into the bloodstream, specific drug-drug interactions involving liver metabolism (CYP450 enzymes) or drug transporters are not expected to be clinically significant. Consequently, no specific medicines are formally contraindicated for co-administration based on interaction risk, and no mandatory timing separation rules are documented in the official labeling. The label also contains no documented interactions with food, alcohol, supplements, or herbal products for the otic formulation.

Pharmacodynamic Caution and Population Notes

Despite the low systemic absorption, the combination contains components from the fluoroquinolone and corticosteroid drug classes. Regulatory documents note a pharmacodynamic class risk: when these two classes are administered systemically, there is a recognized caution for an increased risk of tendon inflammation and rupture. This risk is particularly noted in elderly patients.

Separately, the official labeling includes a population-specific pharmacokinetic note stating that small increases in plasma concentrations of the active ingredients may be observed when the product is administered to patients with severe hepatic or renal impairment.

Mechanism of Action

Blocking Core Bacterial Replication: DNA Gyrase Inhibition

The antibiotic component, ciprofloxacin, acts by targeting and inhibiting key bacterial enzymes, DNA gyrase (topoisomerase II) and topoisomerase IV. This targeted mechanistic interference prevents the bacteria from replicating or repairing their genetic material, initiating a molecular cascade that leads to rapid bacterial cell death (bacteriolysis).


Modulating Inflammatory Signaling: Glucocorticoid Receptor Agonism

The corticosteroid component, dexamethasone, operates by binding to intracellular glucocorticoid receptors (GRs). This binding modulates the expression of numerous genes, primarily leading to the suppression of pro-inflammatory mediators. The resulting physiological effect is the modulation of tissue edema, nociceptive signaling, and local vasodilation.


Dual-Mechanism Approach: Combined Targeted Modulation

The dual mechanism involves the synergistic action of both components within their respective domains. This combined approach influences core biological systems by simultaneously addressing both bacterial proliferation and the host's inflammatory signaling cascade.

Dosage and Administration Information

How to use Alcon Cilodex — Official Administration Guidelines

Alcon Cilodex (ciprofloxacin/dexamethasone) otic suspension is approved for otic use only (in the ear) in adults and pediatric patients aged 6 months and older, and must not be used in the eye or administered by injection or swallowing. Treatment is a fixed, 7-day course and should not be discontinued early, even if symptoms improve.


Dosing and Preparation

  • Dosing Schedule: Four drops (equivalent to 0.14 mL of the suspension) instilled into the affected ear(s) twice daily (morning and evening) for seven consecutive days.
  • Preparation: The bottle must be shaken well immediately before use. To prevent dizziness that may result from instilling a cold solution, the suspension should be warmed by holding the bottle in the hand for one or two minutes.

Administration Procedure

  1. Wash hands before handling the bottle.
  2. The patient should lie with the affected ear upward.
  3. Instill four drops into the ear canal. Take care to not touch the dropper tip to the ear, fingers, or any other surface to prevent contamination.
  4. Specific Technique (Otitis Media with Tubes): For patients with a tympanostomy tube, the skin flap at the ear canal entrance (tragus) must be gently pressed five times in a pumping motion to help the drops penetrate the middle ear.
  5. Maintain Position: The patient must remain with the ear upward for 60 seconds to facilitate drop penetration.

Missed and Unused Doses

If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should return to the regular schedule. Do not double the dose. After the 7-day course is completed, discard any unused portion of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ciprofloxacin and Dexamethasone

The clinical research was studied for Acute Otitis Externa (AOE) in short-term, comparative clinical trials, involving pediatric patients (age six months and older), adults, and older adults. These studies were often organized as Randomized Controlled Trials (RCTs) against established combination ear drops. The research examined symptom patterns by measuring outcomes related to physical discomfort and the rate of microbiological eradication of the bacterial pathogen. Studies monitored patterns in the rates of clinical resolution when administered alongside comparator drops.

For the treatment of Acute Otitis Media in pediatric patients who have had ear tubes placed (AOMT), the evidence base also consists of comparative clinical trials. The primary endpoints studied in these trials were the rate of clinical resolution and the time to cessation of otorrhea (ear discharge). Comparative trials monitored patterns in the rates of clinical resolution that indicated differences when compared to a single-agent otic solution. Research describes how outcomes linked to inflammatory states evolved when comparing the dual-action medicine to ciprofloxacin administered alone.

Research does not determine whether an individual will respond similarly. The clinical trials specifically included and evaluated pediatric patients who had acute ear infections, starting at six months of age. However, the evidence highlights that long-term effects are not fully established because the primary evidence focused on short-term efficacy. The final assessments in the core clinical trials were generally conducted within 15 to 18 days of beginning treatment. Consequently, there is limited information for long-term outcomes, and data for certain patient subgroups remain insufficient.

Key Studies & References

  1. Ciprofloxacin and Dexamethasone Otic
  2. Ciprofloxacin/dexamethasone otic suspension in the treatment of acute otitis media in children with tympanostomy tubes
  3. NIH Clinical Trial Summary: Ciprofloxacin/Dexamethasone Otic Trial

Frequently Asked Questions (FAQ)

Common questions about Alcon Cilodex (FAQ)


Q: Is Cilodex safe for children, and at what age can it be used?

Official product information states that safety and effectiveness are supported for use in pediatric patients six months of age and older. Regulatory documents indicate that there is insufficient clinical experience available for use in children below this age threshold.


Q: Can using Cilodex cause hearing problems or affect my balance?

Reported side effects include dizziness and other Ear and Labyrinth Disorders. Dizziness can sometimes occur if the suspension is not warmed before use. Hearing-related issues are not identified among the common or frequent adverse reactions documented in official labeling.


Q: What are the most common or mild side effects associated with Cilodex?

Based on regulatory documents, the most common reported effects typically occur in 1% to 10% of patients. These are localized reactions, primarily including ear discomfort, ear pain, and ear pruritus (itching).


Q: Does Cilodex interact with common over-the-counter pain relievers?

Official information indicates that due to the medicine's very low absorption into the bloodstream after topical ear use, clinically relevant drug interactions are not expected with most medicines. No specific medicine, including common over-the-counter pain relievers, is formally contraindicated for co-administration in the official labeling.


Q: Is Cilodex considered safe for use during pregnancy or while breastfeeding?

For pregnancy, official documents advise use only when the potential benefit is considered to justify the risks, as human studies are lacking. For lactation (breastfeeding), use involves a decision on whether to discontinue nursing or discontinue the drug, and caution is advised.


Q: Why do some people say they experience a bitter taste after using the drops?

The regulatory safety profile lists taste perversion as a less common reported adverse reaction. Official information states that if the medicine is tasted, it may indicate a non-intact eardrum, a finding that should be discussed with a healthcare provider.


Q: Is it possible to become resistant to the antibiotic in Cilodex over time?

Official labeling states that using the suspension for a period longer than the approved duration may lead to the overgrowth of non-susceptible organisms (such as bacteria or fungi). This may potentially result in the development of bacterial resistance to the antibiotic component, ciprofloxacin.


Q: Can I travel with Cilodex, and how should I handle it on a flight?

The official storage instructions require the suspension to be stored at room temperature and explicitly state that it must not be frozen. The bottle should be kept in its original container and protected from light. No specific regulatory instructions are provided regarding handling related to air pressure changes during flight.


Q: What is the difference between Cilodex and other antibiotic ear drops?

Cilodex is described as a dual-action combination product because it contains two active ingredients: ciprofloxacin (an antibiotic) and dexamethasone (a corticosteroid). This differs from many other ear drops that contain only a single anti-infective agent.


Q: How long does it typically take to start feeling better after using Cilodex?

Clinical trials and patient instructions often indicate that most patients may experience an improvement in their symptoms within the first few days of starting treatment. Official guidance emphasizes completing the entire fixed seven-day course, even if symptom improvement is noted early.


Q: Why are there two main ingredients in Cilodex, and what does each one do?

The product is designed to manage both the microbial cause and the resulting inflammation. Ciprofloxacin is an antibiotic that works to kill the bacteria causing the infection. Dexamethasone is a corticosteroid that works to reduce the inflammation, swelling, and pain associated with the infection.


Q: Is there a generic version of Cilodex available?

The active ingredient combination, ciprofloxacin and dexamethasone otic suspension, is available from various manufacturers. It may be marketed under different brand names or as an authorized generic version, according to regulatory databases.


Q: What types of bacteria is the ciprofloxacin in Cilodex effective against?

Regulatory documents indicate that the antibiotic component, ciprofloxacin, has documented activity against a wide range of gram-positive and gram-negative microorganisms. This includes bacteria such as Pseudomonas aeruginosa and Staphylococcus species, which are commonly associated with ear infections.


Q: Does Cilodex cause dizziness or affect my ability to drive?

While dizziness is listed as a potential side effect, regulatory documents state that there are no known effects of this otic suspension on the ability to drive or use machines.


Q: Is there a maximum number of days I can safely use Cilodex?

The approved treatment regimen is a fixed course of seven consecutive days. Patients are cautioned that using the product beyond this recommended duration may lead to potential overgrowth of non-susceptible organisms.


Q: Does age affect how well Cilodex works in treating the ear infection?

Clinical trials for the medicine included and evaluated patients across a wide age range, including pediatric patients (six months and older), adults, and older adults. The research evidence described patterns of efficacy across these populations, but does not determine how an individual's response will be affected by their specific age.


Q: What if the Cilodex bottle looks cloudy or changes color?

The product is supplied as a sterile suspension that must be shaken before use. If the suspension changes color, becomes unusually cloudy, or if foreign particles are seen, it is generally advised not to use it. This may indicate that the medicine's quality or stability has been compromised.


Q: Can using too many drops of Cilodex be harmful?

Using more drops than prescribed is not recommended. Official labeling advises that in the event of suspected overdose or if the medicine is accidentally swallowed, a poison control center or emergency room should be contacted immediately.


Q: Does Cilodex help with ear pain or just the infection?

Cilodex is a dual-action medicine. The antibiotic component treats the infection, while the corticosteroid component, dexamethasone, is included specifically to reduce inflammation and modulate the associated symptoms of pain and swelling.

How should Alcon Cilodex be stored and disposed of?

Storage and Disposal Requirements

The official labeling for Alcon Cilodex (ciprofloxacin and dexamethasone otic suspension) provides strict instructions for storage, handling, and disposal to maintain the medicine's quality.

Storage Conditions

The suspension must be stored at room temperature, typically between 20°C and 25°C. It is critically important that the product is not frozen.

  • Protection: The bottle must be kept in its original container and stored tightly closed to protect from light.
  • Child Safety: Keep the medicine out of the sight and reach of children.
  • Stability: The medicine must be discarded 4 weeks (28 days) after first opening, regardless of the amount remaining.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the medicine in drains or wastewater. Before discarding the container, scratch out all identifying information on the label to protect privacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alcon Cilodex found in:

A-Z Index: